TP53 Loss Cancer Clinical Trials

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

147 sites for NCT04293562

BCR-ABL1 Fusion, +48 more biomarkers

Acute Myeloid Leukemia

allogeneic hematopoietic stem cell transplantation, +12 more drugs

cellular therapy, +4 more types

A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

198 sites for NCT04102020

BCR-ABL1 Fusion, +47 more biomarkers

Acute Myeloid Leukemia

azacitidine, +1 more drug

chemotherapy

Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)

14 sites for NCT04571645

ASXL1 Loss, +27 more biomarkers

Acute Myeloid Leukemia

chemotherapy, +1 more drug

chemotherapy, +1 more type

HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors

55 sites for NCT02875314

APC Loss, +67 more biomarkers

Central Nervous System Embryonal Neoplasm, +9 more conditions

carboplatin, +9 more drugs

chemotherapy, +1 more type

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

378 sites for NCT02734537

HPV Negative, +2 more biomarkers

Head and Neck Squamous Cell Carcinoma

cisplatin, +1 more drug

chemotherapy, +1 more type

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

23 sites for NCT01878617

APC Loss, +36 more biomarkers

Intracranial Primitive Neuroectodermal Neoplasm, +1 more condition

cisplatin, +6 more drugs

chemotherapy, +2 more types

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms